| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
3,948 |
3,664 |
$404K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
2,815 |
2,595 |
$391K |
| 87636 |
Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B |
1,109 |
1,088 |
$156K |
| 99393 |
Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) |
558 |
558 |
$71K |
| 99392 |
Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) |
493 |
493 |
$63K |
| 99394 |
Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) |
369 |
369 |
$51K |
| 90460 |
Immunization administration through 18 years of age via any route, first or only component |
2,236 |
2,219 |
$44K |
| 99441 |
|
353 |
339 |
$22K |
| 99391 |
Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) |
179 |
178 |
$22K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
323 |
319 |
$11K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
122 |
121 |
$9K |
| 80050 |
General health panel |
144 |
144 |
$6K |
| 87631 |
|
39 |
39 |
$5K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
345 |
336 |
$5K |
| 96127 |
|
760 |
753 |
$5K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
151 |
148 |
$5K |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
121 |
121 |
$4K |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
121 |
121 |
$4K |
| 80061 |
Lipid panel |
313 |
313 |
$4K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
122 |
121 |
$3K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
44 |
43 |
$3K |
| 87070 |
|
234 |
229 |
$2K |
| 87634 |
|
13 |
13 |
$912.60 |
| 92551 |
|
341 |
341 |
$912.37 |
| 90686 |
|
949 |
948 |
$825.10 |
| 83036 |
Hemoglobin; glycosylated (A1C) |
59 |
59 |
$572.89 |
| 80053 |
Comprehensive metabolic panel |
49 |
49 |
$517.44 |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
54 |
54 |
$419.58 |
| 36415 |
Collection of venous blood by venipuncture |
193 |
190 |
$171.00 |
| 96110 |
Developmental screening, with scoring and documentation, per standardized instrument |
12 |
12 |
$137.50 |
| 85018 |
|
38 |
38 |
$90.06 |
| 96160 |
|
303 |
300 |
$30.72 |
| 99173 |
|
74 |
74 |
$11.43 |
| 90670 |
|
88 |
88 |
$0.00 |
| 90734 |
|
25 |
25 |
$0.00 |
| 90633 |
|
25 |
25 |
$0.00 |
| 90707 |
|
16 |
16 |
$0.00 |
| 36416 |
|
41 |
40 |
$0.00 |
| 90651 |
|
16 |
16 |
$0.00 |
| 90716 |
|
13 |
13 |
$0.00 |
| 90698 |
|
48 |
48 |
$0.00 |
| 90680 |
|
46 |
46 |
$0.00 |